Navigation Links
Modified Citrus Pectin Protects Against Vascular Hardening
Date:11/20/2012

SANTA ROSA, Calif., Nov. 20, 2012 /PRNewswire/ -- Cardiovascular disease will kill nearly 2.5 million people in the United States this year, according to the Centers for Disease Control. Over time, inflammation, collagen deposition and scar tissue formation can cause blood vessels to stiffen, a process called vascular fibrosis. Though researchers have known that the hormone aldosterone (Aldo) plays a role in this process, the precise mechanisms have been poorly understood.

Now, an international study published in Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association is providing new insights into cardiovascular disease. Particularly significant, the study illuminates how Aldo and the protein galectin-3 jointly contribute to vascular remodeling and congestive heart failure by fueling the processes of inflammation, fibrosis and collagen deposition.

The findings indicate that galectin-3 is required for inflammatory and fibrotic responses to Aldo, suggesting a key role for galectin-3 in vascular fibrosis.  Equally important, the study proves that modified citrus pectin (MCP), a preparation derived from the pith of citrus peels, prevents these effects by binding to galectin-3 and controlling Aldo induced elevated galectin-3 levels.

MCP is a form of citrus pectin modified to a specific molecular weight and structure for enhanced absorption and bioactivity. Regular pectin goes through the gastrointestinal tract unabsorbed, whereas MCP is readily absorbed and has been demonstrated in published research to perform multiple beneficial functions. MCP's small molecular weight and unique structure allow it to bind and block excess galectin-3 throughout the body. Elevated serum galectin-3 has been linked to high mortality rates in heart failure and metastatic cancer. MCP slows cancer progression and metastasis, blocks inflammation, helps prevent fibrosis, and offers other critical benefits related to the inhibition of galectin-3. It also supports immunity and safely chelates heavy metals.

Aldo and Galectin-3

The researchers in this study sought to understand exactly how Aldo and galectin-3 work together to affect vascular remodeling. In small quantities, Aldo and galectin-3 perform necessary biological functions. Aldo regulates blood pressure and electrolyte balance; galectin-3 facilitates cell-to-cell communication and cell growth. However, high levels of Aldo are linked to arterial stiffness and heart failure. Similarly, high levels of galectin-3 play a direct role in chronic inflammation, fibrosis and subsequent tissue remodeling in the kidneys, liver, heart and other organs; as well as cancer formation and metastasis.

In 2011, the Food and Drug Administration approved a serum galectin-3 test to assess the risk and progression of congestive heart failure and heart disease. This test is widely available and covered by most health insurances for cardiovascular screening. Practitioners also use this test to assess the risk and progression of cancer and other galectin-3 related diseases.

Dr. Isaac Eliaz, a recognized expert in the field of galectin-3 and the use of modified citrus pectin states, "The results of this study have enormous implications for the prevention and treatment of heart disease and fibrosis related conditions. Because it functions as an active, culprit biomarker, galectin-3 serves as a therapeutic target in multiple life-threatening conditions. According to the scientific literature, this is achievable with the oral application of MCP, a galectin-3 inhibitor without side effects. This approach offers a new solution to numerous chronic conditions related to inflammation, fibrosis and metastatic cancer for which there are limited conventional treatments."

Study Details
In the study, rats were given Aldo and sodium chloride salt, which increased blood pressure, inflammation, fibrosis and galectin-3 levels. Using MCP, the research team blocked excess galectin-3 with significant results. Collagen type 1 deposition, blood pressure, inflammation, fibrosis and aortic wall thickness were all reduced. Spironolactone, a pharmaceutical Aldo inhibitor, achieved similar results.

However, the side effects of spironolactone are significant while MCP is proven to achieve greater results without toxicity or side effects. Specifically, the MCP was shown to outperform spironolactone in a few key areas related to inflammation and fibrosis. MCP achieved better suppression of fibrotic markers. Importantly, MCP completely inhibited the cytokine interleukin-6 (IL-6) which plays a key role in inflammation, fibrosis, immune response and cancer/metastasis. Spironolactone only partially blocked the Aldo induced IL-6.

The team went on to test the impact of increasing Aldo in regular mice as well as in galectin-3 knockout mice unable to produce the protein. When given Aldo, the normal mice experienced the inflammation and overabundant collagen formation associated with vascular remodeling. However, the knock-out mice experienced no ill effects, supporting the conclusion that Aldo requires galectin-3 to induce the collagen type 1 synthesis and deposition associated with vascular fibrosis.

Beyond Heart Disease

This new research confirms a number of earlier studies which implicate galectin-3 in numerous conditions related to inflammation and fibrosis. In particular, it substantiates research published in the journal PLoS One in 2011 demonstrating the role that galectin-3 plays in acute fibrosis-related kidney injuries. That study also shows that MCP blocks the harmful effects of excess galectin-3 and helps to reverse related damages.

This recent study marks a critical step toward understanding the mechanisms behind vascular fibrosis, and the role MCP can play in inhibiting these and other factors associated with heart failure and organ fibrosis. More research must be done to further illuminate the role of galectin-3 in cardiovascular and chronic diseases. Further research including clinical trials are being planned to explore MCP as a safe and natural preventative and treatment for congestive heart failure and metastatic cancer.

For more information on modified citrus pectin call (707) 583-8619, or visit www.mcprecommends.org

Source: Galectin-3 mediates aldosterone-induced vascular fibrosis. Laurent C, Maria M, Pascal R, Victoria C, Ernesto MM, de Boer RA, Françoise P, Patrick L, Faiez Z, Patrick R, Natalia LA. Arterioscler Thromb Vasc Biol. 2012 Nov 1. [Epub ahead of print]

About Better Health Publishing:

Better Health Publishing (BHP) focuses on the publication of key works promoting health and wellness. BHP believes that education and accessible information are the core components of a healthy and sustainable society.

This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.

 


'/>"/>
SOURCE Better Health Publishing
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. One Year After TomoTherapy Acquisition, Accuray on Track to Meet or Exceed Integration Success Metrics And Expecting Near-term Return to Profitability
2. Medbox, Inc. Protects Its Image as a Leader in Sensible Medication Dispensing
3. Sterling Regional protects newborns with electronic device to prevent abductions
4. Novo Nordisk Supports Four San Francisco-based Organizations In Fight Against Diabetes
5. The Princess Margaret BMT Program Chooses Remedy Informatics Blood and Marrow Transplant & Cell Therapy Solutions to Power their fight Against Cancer
6. Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
7. Missouris PSE Blocking Technology Leading To Progress In Battle Against Meth
8. Kentuckys PSE Blocking Technology Leading To Progress In Battle Against Meth
9. GlaxoSmithKline Sales Down in Q3 against Good Underlying Momentum in the Business
10. Harvest Technologies Corporation Files Patent Infringement Complaint against ThermoGenesis Corporation
11. Raging Capital Calls On Taro Pharmaceutical Shareholders To Vote Against The Taro / Sun Pharma Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):